US FDA declines to approve Outlook Therapeutics' drug for eye condition
28/08/2025 11:34
Aug 28 (Reuters) - The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' OTLK.O experimental drug to treat a type of eye condition that causes blurred vision, the company said on Thursday. (Reporting by Unnamalai L, Sriparna Roy and Siddhi Mahatole in Bengaluru; Editing by Mohammed Safi Shamsi) ((Unnamalai.L@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce